File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

TitlePrognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy
Authors
KeywordsPaediatric
Acute myeloid leukaemia
Minimal residual disease
Prognostic factor
Issue Date2015
Citation
British Journal of Haematology, 2015, v. 168, n. 1, p. 94-101 How to Cite?
Abstract© 2014 John Wiley & Sons Ltd. Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.
Persistent Identifierhttp://hdl.handle.net/10722/294472
ISSN
2020 Impact Factor: 6.998
2015 SCImago Journal Rankings: 2.313
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKarol, Seth E.-
dc.contributor.authorCoustan-Smith, Elaine-
dc.contributor.authorCao, Xueyuan-
dc.contributor.authorShurtleff, Sheila A.-
dc.contributor.authorRaimondi, Susana C.-
dc.contributor.authorChoi, John K.-
dc.contributor.authorRibeiro, Raul C.-
dc.contributor.authorDahl, Gary V.-
dc.contributor.authorBowman, William Paul-
dc.contributor.authorTaub, Jeffrey W.-
dc.contributor.authorDegar, Barbara-
dc.contributor.authorLeung, Wing-
dc.contributor.authorDowning, James R.-
dc.contributor.authorPui, Ching Hon-
dc.contributor.authorRubnitz, Jeffrey E.-
dc.contributor.authorCampana, Dario-
dc.contributor.authorInaba, Hiroto-
dc.date.accessioned2020-12-03T08:22:49Z-
dc.date.available2020-12-03T08:22:49Z-
dc.date.issued2015-
dc.identifier.citationBritish Journal of Haematology, 2015, v. 168, n. 1, p. 94-101-
dc.identifier.issn0007-1048-
dc.identifier.urihttp://hdl.handle.net/10722/294472-
dc.description.abstract© 2014 John Wiley & Sons Ltd. Minimal residual disease (MRD) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia (AML) but nearly one-quarter of patients who achieve MRD-negative status still relapse. The adverse prognostic factors among MRD-negative patients remain unknown. We analysed the AML02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD-negative status after either remission induction I or II. By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post-remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.-
dc.languageeng-
dc.relation.ispartofBritish Journal of Haematology-
dc.subjectPaediatric-
dc.subjectAcute myeloid leukaemia-
dc.subjectMinimal residual disease-
dc.subjectPrognostic factor-
dc.titlePrognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bjh.13107-
dc.identifier.pmid25164427-
dc.identifier.pmcidPMC4262553-
dc.identifier.scopuseid_2-s2.0-84915737335-
dc.identifier.volume168-
dc.identifier.issue1-
dc.identifier.spage94-
dc.identifier.epage101-
dc.identifier.eissn1365-2141-
dc.identifier.isiWOS:000346151600012-
dc.identifier.issnl0007-1048-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats